The ongoing review of the EU Pharmaceutical Legislation is looking at recalibrating IP incentives. Intellectual Property fuels medical innovations from the research bench to the patient’s bedside.
Coriolis Pharma extends its service portfolio by integrating RheaVita’s single vial unit (SVU) technology for continuous and controlled freeze-drying to stabilize novel modalities as part of biologics drug product development for clients. MARTINSRIED-MUNICH, Germany, July 31, 2023 / B3C newswire / Cor.
Proceeds will be used to build first GMP compliant biopharmaceutical continuous, controlled, freeze-drying production line and accelerate commercialization of the RheaVita technology First GMP compliant